BioVie Inc. (BIVI) is a pre-revenue clinical-stage pharmaceutical company with no tangible assets of consequence beyond cash and near-cash instruments. Under a liquidation lens, the recovery posture is thin but technically positive at the current snapshot, driven entirely by the cash/T-bill position. As of March 31, 2026, the company reported cash and cash equivalents of $13.1 million (comprising $2.1 million in cash deposits and $11.0 million in U.S. Treasury Bills with maturities of three months or less, all Level 1). Against this, the identifiable liability stack is modest: total operating lease obligations of $296k (present value), accounts payable and accrued expenses (exact balance not separately XBRL-tagged in TAG_CONTEXT but disclosed in MD&A as having decreased by $589k over nine months), and no long-term debt (notes payable were fully retired December 1, 2024). Intangible assets (intellectual property net carrying value of $6,308 at March 31, 2026, down from $178,341 at June 30, 2025) are assigned zero recovery under the liquidation lens. The right-of-use asset of $283k is matched against the operating lease liability of $296k; the ROU asset is haircut to near zero under liquidation assumptions while the lease liability remains at face value, creating a modest net negative from that line. No inventory, no receivables of scale, no PP&E are disclosed. The DOD grant receivable is disclosed in MD&A and cash flow ($69.6k increase) but is not separately XBRL-tagged. The $13.1 million MFFAIS liquidation value approximation is consistent with the disclosed cash position. Equity book value is $15.6 million against an accumulated deficit of $368.6 million; APIC stands at $384.2 million. The going-concern qualification is explicit. Cash burn for the nine months ended March 31, 2026 was $14.9 million in operating outflows, partially offset by $10.5 million from the August 2025 equity offering. At the observed burn rate, the cash runway from the March 31, 2026 balance is approximately ten to eleven months without additional financing. The securities class action and three consolidated derivative lawsuits (In re BioVie Inc. Securities Litigation; In re BioVie Inc. Derivative Litigation) represent contingent liabilities of unquantified magnitude not reflected in any balance sheet accrual; filing does not separately XBRL-tag any litigation reserve. The massive warrant overhang (7.9 million warrants plus 380k prefunded warrants, plus 2.8 million stock options) creates significant potential dilution but no current balance-sheet liability under existing equity classification. Quarter-over-quarter (versus the December 31, 2025 10-Q), cash declined from approximately $20.5 million to $13.1 million, reflecting the acceleration of clinical trial spending in Q3 FY2026 (net loss of $5.3 million for Q3 versus $6.1 million in Q2). The Option Therapeutics subsidiary spin-off of the liver program, noted as a subsequent event in the prior filing, does not appear on the March 31, 2026 balance sheet as a separate asset.
▼ Community Notes